Pathogenesis of Increased Risk of Thrombosis in Cancer

 

 Buy Article Permissions and Reprints

ABSTRACT

Since the observations of Trousseau, not only has the association of cancer and thrombosis been widely recognized but its pathogenesis is now better understood. Attention to the tumor cell as an important source of procoagulants has also contributed to our knowledge of this problem. Tumor cells express tissue factor (TF) and a cancer procoagulant (CP). TF is dormant in the living cell. However, it is activated during apoptosis of the cell, initiating the coagulation cascade and leading to thrombin generation. Because increased apoptosis occurs during treatment with chemotherapeutic agents, hormones, radiation, and hematopoietic growth factors, as well as when there is rapid tumor proliferation, the thrombosis risk is heightened accordingly. These developments have obvious basic and clinical implications.

REFERENCES

• 1 Trousseau A. Phlegmasia alba dolens. In: Clinique Medicale de l'Hotel Dieu de Paris, 2nd ed. Paris: Bailliere 1865 : 654-712
  Google Scholar
• 2 Billroth T. Lectures on surgical pathology and therapeutics. In: A Handbook for Students and Practitioners (translated) London: The New Sydenham Society 1877-1878
  Google Scholar
• 3 Kwaan H C, Lo R, McFadzean A JS. Antifibrinolytic activity in primary carcinoma of the liver.  Clin Sci . 1959;  18 250-261
  PubMedGoogle Scholar
• 4 Rickles F R, Levine M N, Edwards R L. Hemostatic alterations in cancer patients.  Cancer Metastasis Rev . 1992;  11 237-248
  CrossrefPubMedGoogle Scholar
• 5 Falanga A, Barbui T, Rickles F R. et al . Guidelines for clotting studies in cancer patients.  Thromb Haemost . 1993;  70 343-350
  PubMedGoogle Scholar
• 6 Virchow R. Phlogose und Thrombose in Gefäβsystem. In: Gesammelte Abhandlungen zur Wissenschaftlichen Medizin Virchow R, ed. Frankfurt: Von Meidinger Sohn 1856: 458
  Google Scholar
• 7 Rickles F R, Levine M N, Dvorak H F. Abnormalities of hemostasis in malignancy. In: Colman RW, Hirsh J, Marder VJ, et al, eds. Hemostasis and Thrombosis: Basic Principles and Clinical Practice, 4th ed Philadelphia, PA: Lippincott Williams & Wilkins 2001: 1131-1152
  Google Scholar
• 8 O'Meara R AQ, Thornes R D. Some properties of the cancer coagulative factor.  Ir J Med Sci . 1961;  6 106-112
  PubMedGoogle Scholar
• 9 O'Meara R AQ. Coagulative properties of cancers.  Ir J Med Sci . 1958;  6 474-479
  PubMedGoogle Scholar
• 10 Dvorak H F, VanDewater L, Bitzer A M. et al . Procoagulant activity associated with plasma membrane vesicles shed by cultured tumor cells.  Cancer Res . 1983;  43 4334-4342
  PubMedGoogle Scholar
• 11 Carmeliet P, Collen D. Tissue factor.  Int J Biochem Cell Biol . 1998;  30 661-667
  CrossrefPubMedGoogle Scholar
• 12 Greeno E W, Bach R R, Moldow C F. Apoptosis is associated with increased cell surface tissue factor procoagulant activity.  Lab Invest . 1996;  75 281-289
  PubMedGoogle Scholar
• 13 Edwards R L, Morgan D L, Rickels F R. Animal tumor procoagulants: Registry of the Subcommittee on Haemostasis and Malignancy of the Scientific and Standardization Committee, International Society of Thrombosis and Haemostasis.  Thromb Haemost . 1990;  63 133-138
  PubMedGoogle Scholar
• 14 Edwards R L, Silver J, Rickles F R. Human tumor procoagulants: Registry of the Subcommittee on Haemostasis and Malignancy of the Scientific and Standardization Committee, International Society of Thrombosis and Haemostasis.  Thromb Haemost . 1993;  69 205-213
  PubMedGoogle Scholar
• 15 Rickles F R, Hair G A, Schmeizl M. et al . All-trans-retinoic acid (ATRA) inhibits the expression of tissue factor in human progranulocytic leukemia cells (Abst).  Thromb Haemost . 1993;  69 573
  PubMedGoogle Scholar
• 16 Wang J, Weiss I, Svoboda K. et al . Thrombogenic role of cells undergoing apoptosis.  Br J Haematol . 2001;  115 382-391
  CrossrefPubMedGoogle Scholar
• 17 Gale A J, Gordon S G. Update on tumor cell procoagulant factors.  Acta Haematol . 2001;  106 25-32
  CrossrefPubMedGoogle Scholar
• 18 Gordon S G, Cross B A. An enzyme-linked immunosorbent assay for cancer procoagulant and its potential as a new tumor marker.  Cancer Res . 1990;  50 6229-6234
  PubMedGoogle Scholar
• 19 Kozwich D L, Kramer L C, Mielicki W P. et al . Application of cancer procoagulant as an early detection tumor marker.  Cancer . 1994;  74 1367-1376
  PubMedGoogle Scholar
• 20 Mielicki W P, Tenderenda M, Rutkowski P. et al . Activation of blood coagulation and activity of cancer procoagulant (EC 3.4.22.26) in breast cancer patients.  Cancer Lett . 1999;  146 61-66
  CrossrefPubMedGoogle Scholar
• 21 Falanga A, Consonni R, Marchetti M. et al . Cancer procoagulant and tissue factor are differently modulated by all-trans retinoic acid in acute promyelocytic leukemia cells.  Blood . 1998;  92 143-151
  PubMedGoogle Scholar
• 22 Falanga A, Consonni R, Marchetti M. et al . Cancer procoagulant in the human promyelocytic cell line NB4 and its modulation by retinoic acid.  Leukemia . 1994;  8 156-158
  PubMedGoogle Scholar
• 23 Koyama T, Hirosawa S, Kawamata N. et al . All-trans retinoic acid upregulates thrombomodulin and downregulates tissue-factor expression in acute promyelocytic leukemia cells: distinct expression of thrombomodulin and tissue factor in human leukemic cells.  Blood . 1994;  84 3001-3009
  PubMedGoogle Scholar
• 24 De Stefano V, Teofili L, Sica S. et al . Effect of all-trans retinoic acid on procoagulant and fibrinolytic activities of cultured blast cells from patients with acute promyelocytic leukemia.  Blood . 1995;  86 3535-3541
  PubMedGoogle Scholar
• 25 Nierodzik M LR, Bain R M, Liu L X. et al . Presence of the seven transmembrane thrombin receptor on human tumor cells: effect of activation on tumor adhesion to platelets and tumor tyrosine phosphorylation.  Br J Haematol . 1996;  92 452-457
  CrossrefPubMedGoogle Scholar
• 26 Yoshida E, Verrusio E N, Mihara H. et al . Enhancement of the expression of urokinase-type plasminogen activator from PC-3 human prostate cancer cells by thrombin.  Cancer Res . 1994;  54 3300-3304
  PubMedGoogle Scholar
• 27 Yoshida E, Verrusio E N, Mihara H. et al . Thrombin stimulates expression of the receptor for urokinase-type plasminogen activator in DU-145 prostate cancer cells.  Fibrinolysis Proteolysis . 1997;  11 147-154
  PubMedGoogle Scholar
• 28 Nierodzik M L, Kajumo F, Karpatkin S. Effect of thrombin treatment of tumor cells on adhesion of tumor cells to platelets in vivo and tumor metastasis in vivo.  Cancer Res . 1992;  52 3267-3272
  PubMedGoogle Scholar
• 29 McNamara C A, Sarembok I J, Gimple L W. Thrombin stimulation of smooth muscle proliferation is mediated by a proteolytic, receptor-mediated mechanism.  J Clin Invest . 1992;  91 94-98
  PubMedGoogle Scholar
• 30 Nierodzik M L, Plotkin A, Kajumo F. et al . Thrombin stimulates tumor-platelet adhesion in vivo.  J Clin Invest . 1991;  87 229-236
  CrossrefPubMedGoogle Scholar
• 31 Nierodzik M L, Bain R M, Liu L X. et al . Presence of the seven transmembrane thrombin receptor on human tumour cells: effect of activation on tumour adhesion to platelets and tumour tyrosine phosphorylation.  Br J Haematol . 1996;  92 452-457
  CrossrefPubMedGoogle Scholar
• 32 Klepfish A, Greco M A, Karpatkin S. Thrombin stimulates melanoma tumor-cells binding to endothelial cells and sub-endothelial matrix.  Int J Cancer . 1993;  53 978-982
  PubMedGoogle Scholar
• 33 Wun T C, Kretzmer K K, Girard T J. et al . Cloning and characterization of a cDNA coding for the lipoprotein-associated coagulation inhibitor shows that it consists of the three tandem Kunitz-type inhibitory domains.  J Biol Chem . 1988;  263 6001-6004
  Google Scholar
• 34 Girard T J, Warren L A, Novotny W F. et al . Functional significance of the Kunitz-type inhibitory domains of lipoprotein-associated coagulation inhibitor.  Nature . 1989;  338 518-520
  Google Scholar
• 35 Rao L V, Rapaport S I. Studies of a mechanism inhibiting the initiation of the extrinsic pathway of coagulation.  Blood . 1987;  69 645-651
  PubMedGoogle Scholar
• 36 Lindahl A K, Ødegaard O R, Sandset P M. et al . Coagulation inhibition and activation in pancreatic cancer.  Cancer . 1992;  70 2067-2072
  PubMedGoogle Scholar
• 37 Lindahl A K, Sandset P M, Abildgaard U. et al . High levels of extrinsic pathway inhibitor and low levels of other coagulation inhibitors in advanced malignant disease.  Acta Chir Scand . 1989;  155 389-393
  Google Scholar
• 38 Iversen N, Lindahl A-K, Abildgaard U. Elevated TFPI in malignant disease: relation to cancer type and hypercoagulation.  Br J Haematol . 1998;  102 889-895
  CrossrefPubMedGoogle Scholar
• 39 Wojtukiewicz M Z, Zacharski L R, Rucinska M. et al . Expression of tissue factor and tissue factor pathway inhibitor in situ in laryngeal carcinoma.  Thromb Haemost . 1999;  82 1659-1662
  PubMedGoogle Scholar
• 40 Bajaj M S, Kuppuswamy M N, Saito H. et al . Cultured normal human hepatocytes do not synthesize lipoprotein-associated coagulation inhibitors: evidence that endothelium is the principal site of its synthesis.  Proc Natl Acad Sci USA . 1990;  87 8869-8873
  Google Scholar
• 41 Ameri A, Kuppuswamy M N, Basu S. et al . Expression of tissue factor pathway inhibitor by cultured endothelial cells in response to inflammatory mediators.  Blood . 1992;  79 3219-3226
  PubMedGoogle Scholar
• 42 Kwaan H C. The plasminogen-plasmin system in malignancy.  Cancer Met Rev . 1992;  11 291-311
  CrossrefPubMedGoogle Scholar
• 43 Carroll V A, Binder B R. The role of the plasminogen activation system in cancer.  Semin Thromb Hemost . 1999;  25 183-197
  Article in Thieme ConnectPubMedGoogle Scholar
• 44 Heittiarachchi R JK, Lok J, Prins M H. et al . Undiagnosed malignancy in patients with DVT. Incidence, risk indicators and diagnosis.  Cancer . 1998;  83 100-105
  PubMedGoogle Scholar
• 45 Sørenson H, Mallemakjaer L, Steffen F H. et al . The risk of diagnosis of cancer after primary DVT or PE.  N Engl J Med . 1998;  338 1169-1174
  CrossrefPubMedGoogle Scholar
• 46 Baron J A, GridleyG, Weiderpass E. et al . Venous thromboembolism and cancer.  Lancet . 1998;  351 1077-1080
  CrossrefPubMedGoogle Scholar
• 47 Monreal M, Prandoni P. Venous thromboembolism as first manifestation of cancer.  Semin Thromb Haemost . 1999;  25 131-136
  PubMedGoogle Scholar
• 48 Picioli A, Prandoni P. Venous thromboembolism as first manifestation of cancer.  Acta Haematol . 2001;  106 13-17
  CrossrefPubMedGoogle Scholar
• 49 Tallman M S, Kwaan H C. Reassessing the hemostatic disorder associated with acute promyelocytic leukemia.  Blood . 1992;  79 543-553
  PubMedGoogle Scholar
• 50 Golomb H, Rowley J D, Vardiman J W. et al . Microgranular acute promyelocytic acute leukemia: a distinct clinical, ultrastructural and cytogenetic entity.  Blood . 1980;  55 253-259
  PubMedGoogle Scholar
• 51 Menell J S, Cesarman G M, Jacovina A T. et al . Annexin II and bleeding in acute promyelocytic leukemia.  N Engl J Med . 1999;  340 994-1004
  CrossrefPubMedGoogle Scholar
• 52 Falanga A, Alessio M G, Donati M B. et al . A new procoagulant in acute leukemia.  Blood . 1988;  71 870-875
  PubMedGoogle Scholar
• 53 Donati M B, Falanga A, Consonni R. et al . Cancer procoagulant in non lymphoid leukemia: relationship of enzyme detection to disease activity.  Thromb Haemost . 1990;  64 11-16
  PubMedGoogle Scholar
• 54 Bennett B, Booth A, Croll A. et al . The bleeding disorder in acute promyelocytic leukemia: fibrinolysis due to u-PA rather than defibrination.  Br J Haematol . 1989;  71 511-517
  CrossrefPubMedGoogle Scholar
• 55 Francis R B, Seyfert U. Tissue plasminogen activator antigen and activity in disseminated intravascular coagulation. Clinicopathologic correlations.  J Lab Clin Med . 1987;  110 541-547
  PubMedGoogle Scholar
• 56 Stephens R, Alitalo R, Tapiovaara H. et al . Production of an active urokinase by leukemia cells. A novel distinction from cell lines of solid tumors.  Leuk Res . 1988;  12 419-422
  CrossrefPubMedGoogle Scholar
• 57 Naschitz J E, Yeshurn D, Eldar S. et al . Diagnosis of cancer associated vascular disorders.  Cancer . 1996;  77 1759-1767
  CrossrefPubMedGoogle Scholar
• 58 Levine M N. Prevention of thrombotic disorders in cancer patients undergoing chemotherapy.  Thromb Haemost . 1997;  78 133-136
  PubMedGoogle Scholar
• 59 Doll D C, Yarbro J W. Vascular toxicity associated with antineoplastic agents.  Semin Oncol . 1992;  19 580-596
  PubMedGoogle Scholar
• 60 von Templehoff F G, Dietrich M, Hommel G. et al . Blood coagulation during adjuvant epirubicin/cyclophosphamide chemotherapy in patients with primary operable breast cancer.  J Clin Oncol . 1996;  14 2560-2568
  PubMedGoogle Scholar
• 61 Saphner T, Tormey D C, Gray R. Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer.  J Clin Oncol . 1991;  9 286-294
  PubMedGoogle Scholar
• 62 Goodnough L T, Saito H, Manni A. et al . Increased incidence of thromboembolism in stage IV breast cancer patients treated with a five drug chemotherapy regimen.  Cancer . 1984;  54 1264-1268
  CrossrefPubMedGoogle Scholar
• 63 Oberhoff C, Winkler U H, Tauchert A M. et al . Adjuvant CMF chemotherapy in patients with breast cancer-results on blood coagulation and fibrinolysis.  Zentralbl Gynäkol . 1997;  119 211-217
  PubMedGoogle Scholar
• 64 Bertomeu M C, Gallo S, Lauri D. et al . Chemotherapy enhances endothelial cell reactivity to platelets.  Clin Exp Met . 1990;  8 511-518
  CrossrefPubMedGoogle Scholar
• 65 Pemberton K D, Melissari E, Kakkar V V. The influence of tamoxifen in vivo on the main natural anticoagulants and fibrinolysis.  Blood Coagul Fibrinolysis . 1993;  4 935-942
  PubMedGoogle Scholar
• 66 Jankowski J, Ramlau C, Kopczynski Z. et al . Influence of tamoxifen on plasma coagulation and serous fibrinolysis.  Eur J Gynaecol Oncol . 1993;  14(Suppl) 155-158
  PubMedGoogle Scholar
• 67 Cohen L F, Balow J E, Magrath I T. et al . Acute tumor lysis syndrome: a review of 37 patients with Burkitt's lymphoma.  Am J Med . 1980;  68 486-491
  CrossrefPubMedGoogle Scholar
• 68 Haas M, Ohler L, Watzke H. et al . The spectrum of acute renal failure in tumor lysis syndrome.  Nephrol Dial Transplant . 1999;  14 776-779
  PubMedGoogle Scholar
• 69 Fleming D R, Doukas M A. Acute tumor lysis syndrome in hematologic malignancies.  Leuk Lymphoma . 1992;  8 315-318
  PubMedGoogle Scholar
• 70 Jasek A M, Day H G. Acute spontaneous tumor lysis syndrome.  Am J Hematol . 1994;  47 129-131
  CrossrefPubMedGoogle Scholar